Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease

NCT03221257 is registered in ClinicalTrials.gov with Michael Roth as lead sponsor.

NCT NCT03221257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03221257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Lead sponsor
Michael Roth
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2017
Completion date
June 13, 2022
Enrollment
51 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, scleroderma, systemic